Trial Profile
Pharmacokinetic study of Cc-292 in healthy subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Apr 2016
Price :
$35
*
At a glance
- Drugs Spebrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacokinetics
- 25 Apr 2016 New trial record
- 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics